This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Successfully Balancing The Needs of The Planet With The Needs of The Patient
Publications, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Product Solutions
Using digital healthcare to improve patient compliance and adherence
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions
Introducing PureHale® for targeted upper respiratory tract care
Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation
Aptar Pharma talks targeted drug delivery to the upper airways
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation
